Juvenescence joins the 200M Fund portfolio in the investment in Chrysea Labs (“Chrysea”), a synthetic biology company developing high-value and difficult to source natural products, using proprietary synthetic biology platforms.
A recent study published in the Journal of American Nutrition Association shows that bis hexanoyl (R)-1,3-butanediol (BH-BD), the active ingredient in Metabolic Switch™, induces ketosis.
January 5 is National Keto Day. Started two years ago by The Vitamin Shoppe, the day serves to bring awareness to the ketogenic diet and its health benefits.
Juvenescence Ltd., a longevity biotech and life sciences company announced the launch of Metabolic Switch, an evidence-based, breakthrough C6 Ketone Di-ester drink that puts the consumer in ketosis to promote...
Juvenescence announces that Dr. Grazia Piizzi has joined its Executive Management Team as Chief Scientific Officer.
AgeX Therapeutics and LyGenesis announced today that they will proceed to negotiate an agreement for a merger of the two companies.
Juvenescence announces a partnership with Evgen Pharma PLC to license its sulforaphane Sulforadex® stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.
Juvenescence Limited and G3 Therapeutics announced the formation of Juvenomics Limited, a joint venture between the two parent companies.
NetraMark Corp. and Juvenescence are excited to announce the extension of their collaboration agreement to include drug repurposing and drug discovery.
Juvenescence, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity.
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.